Localised prostate cancer can be stratified into three groups based on the likelihood of tumour spread and recurrence: Low-risk: PSA <10 ng/mL, and biopsy Gleason score ≤6, and clinical stage T1 T2a Intermediate-risk: PSA 10 20 ng/mL, or biopsy Gleason score 7, or clinical stage T2b or T2c High-risk: PSA >20 ng/mL, or Gleason score 8 10, or clinical stage >T2c.
In univariate analysis, three gene-expression levels were found to be significantly associated with an increased locoregional recurrence rate: low ERβ, low aromatase, high GATA3 (Table 3).
Expression of three genes was found to be significantly associated with an increased locoregional recurrence rate: low estrogen-receptor β, low aromatase, and high GATA3.
Because the absolute risk of local recurrence is low, however, differences in the rates of recurrence are small.
The high rates of recurrence and low median survival in many B-cell cancers highlight a need for new targeted therapeutic modalities.
Disruption of cortical representation, or body schema, has been indicated as a factor in the persistence and recurrence of low back pain (LBP).
The rate of recurrence was low (2.8%).
In addition, we assessed the recurrence risk (low vs high) using the 70-gene MammaPrint™ signature.
If the local recurrence was low seated, the perineum was included in the radiation volume.
The risk of IMLN recurrence is low and there are certain characteristics features on CT images.
Drug resistance is a cause of ovarian cancer recurrence and low overall survival rates.
